• In late July 2026, Healthcare Realty Trust filed shelf registrations covering up to US$775.08 million of securities, reported a second-quarter 2026 net loss of US$43.51 million on US$281.85 million in revenue, affirmed a US$0.24 per-share dividend, and updated full-year 2026 guidance to a loss per share between US$0.15 and US$0.11.
• Alongside these filings and results, the company kept its dividend intact while having completed US$99.88 million of prior share repurchases, underscoring a continued focus on shareholder returns even as losses narrowed year over year.
• We’ll now examine how the expanded shelf registration, alongside updated 2026 loss guidance, reshapes Healthcare Realty Trust’s broader investment narrative.

AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Healthcare Realty Trust Investment Narrative Recap

To own Healthcare Realty Trust, you need to be comfortable with a REIT that is still loss making while leaning on demographic demand for outpatient care and ongoing operational improvements. The key near term catalyst remains execution in leasing and occupancy, while the biggest risk is that operational restructuring and asset investment fail to translate into the targeted NOI uplift. The new US$775.08 million shelf and wider 2026 loss guidance do not materially alter that risk balance in the short term.

The most relevant development here is the lowered 2026 loss per share guidance to a US$0.15 to US$0.11 range. That revision puts more emphasis on whether the company can deliver cost efficiencies and margin improvement from its newer management and board, since any slip in execution could keep net margins under pressure even as healthcare demand trends stay supportive.

Yet investors should be aware that if the shift from a deal focused to an operations focused model stumbles...

Healthcare Realty Trust's narrative projects $1.2 billion revenue and $221.9 million earnings by 2029.

Uncover how Healthcare Realty Trust's forecasts yield a $21.08 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$21.08 to US$31.98 per share, showing a wide spread of individual views. Against that backdrop, the company’s lowered 2026 loss guidance and ongoing operational transition mean you may want to compare several of these perspectives before forming your own expectations for Healthcare Realty Trust’s performance.

Explore 2 other fair value estimates on Healthcare Realty Trust - why the stock might be worth as much as 60% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Healthcare Realty Trust research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Healthcare Realty Trust research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Healthcare Realty Trust's overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.